# Iolyx Therapeutics

**Canonical:** https://apis.io/providers/iolyx-therapeutics/  
**Website:** https://iolyx.com/  
**APIs profiled:** 0

Iolyx Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Burlingame, California, working at what it calls the intersection of immunology and ophthalmology — "immuno-ophthalmology". The company develops immunomodulatory therapeutics that target ocular inflammation at its source, using what it describes as innovative pathways and tailored formulations for precise delivery to the relevant ocular tissues, positioned as an alternative to conventional steroids and broad immunosuppressants. Its lead asset, ILYX-002, is in trials for autoimmune-associated dry eye disease; the company announced Phase 2 results in May 2025 and, in December 2025, a strategic agreement with Laboratoires Théa to develop and commercialize ILYX-002 alongside Series B funding for its retinal pipeline. The stated pipeline spans front-of-eye indications (dry eye, ocular allergy, rosacea, uveitis) and back-of-eye indications (age-related macular degeneration, diabetic retinopathy, posterior uveitis). Iolyx is a drug developer rather than a software vendor: it operates a six-page WordPress marketing site at iolyx.com and publishes no public API, developer portal, SDK, or machine-readable specification.

## Kin Score — 3.3 / 100 (minimal)

Scored 2026-08-25 under rubric 0.14.0. Trend: flat (+0.0 from 3.3).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Security (1)

- **Iolyx Therapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Healthcare, Biotechnology, Pharmaceuticals, Life Sciences, Ophthalmology, Immunology, Clinical Trials

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/iolyx-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.